Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister A, Lucraft HH, Radford J, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group. Swerdlow AJ, et al. Among authors: bates a. J Natl Cancer Inst. 2014 Aug 19;106(9):dju207. doi: 10.1093/jnci/dju207. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25139687
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV. Swerdlow AJ, et al. Among authors: bates a. J Clin Oncol. 2012 Aug 1;30(22):2745-52. doi: 10.1200/JCO.2011.38.8835. Epub 2012 Jun 25. J Clin Oncol. 2012. PMID: 22734026
Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.
Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Illidge T, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group; Swerdlow AJ. Cooke R, et al. Br J Cancer. 2013 Jun 11;108(11):2399-406. doi: 10.1038/bjc.2013.219. Epub 2013 May 7. Br J Cancer. 2013. PMID: 23652303 Free PMC article.
Recommendations for Radiotherapy Technique and Dose in Extra-nodal Lymphoma.
Hoskin PJ, Díez P, Gallop-Evans E, Syndikus I, Bates A, Bayne M; Participants of the National Cancer Research Institute Lymphoma Radiotherapy Group. Hoskin PJ, et al. Among authors: bates a. Clin Oncol (R Coll Radiol). 2016 Jan;28(1):62-8. doi: 10.1016/j.clon.2015.09.005. Epub 2015 Oct 9. Clin Oncol (R Coll Radiol). 2016. PMID: 26456507
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW. Illidge TM, et al. Among authors: bates a. Br J Haematol. 2016 Apr;173(2):274-82. doi: 10.1111/bjh.13954. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26849853 Free article. Clinical Trial.
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.
Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, McKinna F, Madhavan K, Bates A, O'Rourke N, Lester JF, Sevitt T, Roos D, Brown G, Thomas SS, Forsyth S, Reczko K, Hackshaw A, O'Hara C, Lopes A. Hoskin PJ, et al. Among authors: bates a. Radiother Oncol. 2022 Aug;173:77-83. doi: 10.1016/j.radonc.2022.05.017. Epub 2022 May 23. Radiother Oncol. 2022. PMID: 35618101 Clinical Trial.
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, Dubois D, McKinna F, Foran B, Madhavan K, MacGregor C, Bates A, O'Rourke N, Lester JF, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas SS, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A. Hoskin PJ, et al. Among authors: bates a. JAMA. 2019 Dec 3;322(21):2084-2094. doi: 10.1001/jama.2019.17913. JAMA. 2019. PMID: 31794625 Free PMC article. Clinical Trial.
227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.
Lindén O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. Lindén O, et al. Among authors: bates at. Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21. Cancer Biother Radiopharm. 2021. PMID: 33887152 Clinical Trial.
Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F. Illidge TM, et al. Among authors: bates at. J Clin Oncol. 2014 Jan 20;32(3):212-8. doi: 10.1200/JCO.2013.50.3110. Epub 2013 Dec 2. J Clin Oncol. 2014. PMID: 24297953 Clinical Trial.
803 results